跳到正文
BiotechTV - News(podcasters.spotify.com)· BiotechTV·· 12 天前品質評分58

STIFEL 2026: Alkermes' new CEO Blair Jackson describes his priorities for the company - which include a heavy focus on the emerging orexin agonist class

STIFEL 2026: Alkermes' new CEO Blair Jackson describes his priorities for the company - which include a heavy focus on the emerging orexin agonist class

重點導讀

He describes the profile of the company's orexin and its development path (a key trial in Idiopathic Hypersomnia will be reading out soon), which also includes indications like ADHD, MS, and Parkinson's further on down the line. Plus how the acquisition of Avadel has been a fit, and whether he would consider doing additional deals.

AI 伴隨問答

自備 Key 深度分析

針對這篇報導有疑問?可直接點選快捷問題或向 AI 追問背景脈絡與技術細節:

Podcast 專家音訊節目

收錄於 888news Podcast 智庫專區,包含精華摘要與上市公司即時行情

正文

He describes the profile of the company's orexin and its development path (a key trial in Idiopathic Hypersomnia will be reading out soon), which also includes indications like ADHD, MS, and Parkinson's further on down the line. Plus how the acquisition of Avadel has been a fit, and whether he would consider doing additional deals.

來源: BiotechTV - News (podcasters.spotify.com)
開啟原文

讀者討論

理性交流 · 即時討論